Author Sarah Gray shares her story of how she anonymously donated her infant son’s post-mortem tissue for biomedical research to some of the most prestigious scientific facilities in the country. Years later, after tracking down each donation, Sarah met with the research scientists that received the donations to learn how they are being studied in cutting-edge research for medical discoveries. One of these research scientists who received her son’s retinas is Dr.
Join our distinguished Novartis speaker, Shruthi Bharadwaj, PhD as she speaks about her experience in AI including: With the costs to commercialize a new drug is dramatically increasing to over $2 billion, AI brings the opportunity to assist pharma companies to bring new drugs and therapies to the market faster.
Certain disease studies exploring sensitive biomarkers or molecules with a short half-life require blood analysis soon after collection to prevent important blood components from breaking down, which may have a negative effect on study results. Numerous factors such as diet, medications, supplements, and patient hydration can affect blood test results.
Antibodies in recovered victums’ blood may hold key to COVID-19 cure In the race to develop treatments for the coronavirus, two California biotech companies are teaming up to collect blood samples from people who have recovered from COVID-19 — with the hope that antibodies produced by their immune system after being infected can provide the key to developing a drug or vaccine.
The largest barrier to conducting clinical research is the high cost. According to the Tufts Center for the Study of Drug Development (CSDD), it now costs up to $2.6 billion to bring a new drug to market, up from $1 billion from the 1990s to the early 2000s, and costs are continuing to rise.
Rheumatoid arthritis (RA) is an autoimmune disorder characterized by joint swelling, pain, and damage from chronic inflammation. RA occurs in roughly 5 per 1,000 people and may cause severe and irreversible joint damage and debilitation1. The key to combating RA is early diagnosis and treatment with various anti-inflammatory agents collectively known as disease-modifying antirheumatic drugs (DMARDs), which can prevent or slow joint damage in 90% of patients.
Hepatitis B virus (HBV) is the world’s most common cause of chronic viral infection. Individuals may become infected through contact with bodily fluids or from mother to child during birth. Some people with acute HBV infections experience symptoms like vomiting, yellowish skin, dark urine, fatigue, and abdominal pain, while others feel no symptoms at all.
People with Duchenne muscular dystrophy (DMD) suffer from a range of muscular issues, including a loss of motor, pulmonary, and cardiac functions, which eventually leads to death. Early signs of the disease include developmental delays, enlarged calf muscles, a waddling gait, generalized muscle weakness, and difficulty performing physical activities.
Biobanks store various biological samples for research use. Although they have become an important resource for researchers since their introduction in the late 1990s, biobanks provide limited samples and associated information. Sanguine sought to overcome challenges commonly encountered with biobanks by creating a universal protocol for delivering quality standardized biospecimens to the biomedical research community.
Systemic lupus erythematosus (SLE) is a complex disease characterized by numerous clinical manifestations related to acute disease activity or chronic damage. Distinguishing between active, potentially treatable symptoms and permanent damage is critical for SLE research and in clinical care settings. However, assessing disease activity in SLE patients is a challenge for physicians and researchers due to the complexity of the condition and fluctuating levels of symptoms involving one or multiple organs.